Developing a model to predict risks of iodine contrast medium extravasation
Development and Validation of a Risk Prediction Model for Iodinated Contrast Medium Extravasation in Patients Undergoing Contrast-enhanced Computed Tomography
This study is trying to create a tool to help doctors predict which patients might have problems with iodine contrast during CT scans, so they can manage the risks better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06859242 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a risk prediction model for iodine contrast agent extravasation during enhanced CT examinations. It employs a retrospective case-control design, comparing patients who experienced extravasation with those who did not. Data collected includes demographic information, medical history, examination parameters, venous access details, and environmental factors. The goal is to implement this model clinically to enhance risk management for iodine contrast agent extravasation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients undergoing enhanced CT examinations who are willing to participate and do not have contraindications to iodine contrast.
Not a fit: Patients with iodine contrast allergies, hyperthyroidism, or those in critical condition may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could significantly reduce the incidence of iodine contrast medium extravasation and improve patient safety during CT examinations.
How similar studies have performed: While similar predictive models have been explored, this specific approach to iodine contrast extravasation is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Volunteer to participate in this study. 2. Without contraindications such as iodine contrast allergy or hyperthyroidism. - Exclusion Criteria: 1. There are communication barriers between researchers and patients. 2. Due to critical condition or unstable vital signs, patients should be transferred to relevant clinical departments for treatment or observation immediately after examination.
Where this trial is running
Wuhan, Hubei
- TongjiHospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Wenyan Zhang, Master — Tongji Hospital
- Study coordinator: Wenyan Zhang, Master
- Email: callmeanna1986@163.com
- Phone: 0086-027-83663493
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.